Cargando…

An unsuspected complication with immune checkpoint blockade: a case report

BACKGROUND: Immunotherapy treatment with immune-checkpoint blockade has become a new paradigm in cancer treatment. Despite its efficacy, it has also given rise to a new class of adverse events, immune-related adverse events, which may affect any organ, including the thyroid and the pituitary. CASE P...

Descripción completa

Detalles Bibliográficos
Autores principales: Carril-Ajuria, Lucia, Jiménez-Aguilar, Elisabeth, Gómez-Martín, Carlos, Díaz-Pedroche, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122676/
https://www.ncbi.nlm.nih.gov/pubmed/30176934
http://dx.doi.org/10.1186/s13256-018-1782-0
_version_ 1783352700988030976
author Carril-Ajuria, Lucia
Jiménez-Aguilar, Elisabeth
Gómez-Martín, Carlos
Díaz-Pedroche, Carmen
author_facet Carril-Ajuria, Lucia
Jiménez-Aguilar, Elisabeth
Gómez-Martín, Carlos
Díaz-Pedroche, Carmen
author_sort Carril-Ajuria, Lucia
collection PubMed
description BACKGROUND: Immunotherapy treatment with immune-checkpoint blockade has become a new paradigm in cancer treatment. Despite its efficacy, it has also given rise to a new class of adverse events, immune-related adverse events, which may affect any organ, including the thyroid and the pituitary. CASE PRESENTATION: We present a case of a 77-year-old Caucasian man with metastatic renal cell carcinoma on immunotherapy treatment who was admitted to our hospital with a severe persistent headache of sudden onset. He had been on corticosteroid therapy for 10 days for suspected immune-related thyroiditis. The patient had tachycardia and mild diarrhea, and his thyroid function tests were compatible with subclinical hyperthyroidism with a suppressed thyroid-stimulating hormone level of 0.01 μIU/ml (0.4–4.5), a raised free T4 level of 2.17 ng/dl (0.7–1.9), and a free T3 level of 4.66 pg/ml (2.27–5). Computed tomography and magnetic resonance imaging revealed an enlargement of the pituitary gland compatible with macroadenoma. In the face of a probable immune-related hypophysitis, high-dose corticosteroid treatment was started. A posterior hormonal evaluation revealed secondary hypothyroidism with a suppressed thyroid-stimulating hormone level of 0.11 μIU/ml (0.4–4.5) and low thyroid hormones, a normal free T4 level of 1.02 ng/dl (0.7–1.9), and a low free T3 level of 1.53 pg/ml (2.27–5). These new findings suggested central hypothyroidism possibly due to pituitary apoplexy as a complication of the macroadenoma. Therefore, levothyroxine substitution was started along with the previously started corticosteroid therapy. The patient’s headache and asthenia gradually resolved, and after a few days, he was released from the hospital with levothyroxine substitution and corticosteroid tapering. CONCLUSIONS: This case emphasizes the importance of the differential diagnosis when dealing with patients on immune checkpoint inhibitors because other non-immune-related events may present. Our patient was finally diagnosed with immune-related hyperthyroidism and a concurrent pituitary macroadenoma. This case also highlights the importance of a prompt start of corticosteroid therapy once immune-related adverse events such as hypophysitis are suspected, because otherwise the outcome would be fatal.
format Online
Article
Text
id pubmed-6122676
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61226762018-09-10 An unsuspected complication with immune checkpoint blockade: a case report Carril-Ajuria, Lucia Jiménez-Aguilar, Elisabeth Gómez-Martín, Carlos Díaz-Pedroche, Carmen J Med Case Rep Case Report BACKGROUND: Immunotherapy treatment with immune-checkpoint blockade has become a new paradigm in cancer treatment. Despite its efficacy, it has also given rise to a new class of adverse events, immune-related adverse events, which may affect any organ, including the thyroid and the pituitary. CASE PRESENTATION: We present a case of a 77-year-old Caucasian man with metastatic renal cell carcinoma on immunotherapy treatment who was admitted to our hospital with a severe persistent headache of sudden onset. He had been on corticosteroid therapy for 10 days for suspected immune-related thyroiditis. The patient had tachycardia and mild diarrhea, and his thyroid function tests were compatible with subclinical hyperthyroidism with a suppressed thyroid-stimulating hormone level of 0.01 μIU/ml (0.4–4.5), a raised free T4 level of 2.17 ng/dl (0.7–1.9), and a free T3 level of 4.66 pg/ml (2.27–5). Computed tomography and magnetic resonance imaging revealed an enlargement of the pituitary gland compatible with macroadenoma. In the face of a probable immune-related hypophysitis, high-dose corticosteroid treatment was started. A posterior hormonal evaluation revealed secondary hypothyroidism with a suppressed thyroid-stimulating hormone level of 0.11 μIU/ml (0.4–4.5) and low thyroid hormones, a normal free T4 level of 1.02 ng/dl (0.7–1.9), and a low free T3 level of 1.53 pg/ml (2.27–5). These new findings suggested central hypothyroidism possibly due to pituitary apoplexy as a complication of the macroadenoma. Therefore, levothyroxine substitution was started along with the previously started corticosteroid therapy. The patient’s headache and asthenia gradually resolved, and after a few days, he was released from the hospital with levothyroxine substitution and corticosteroid tapering. CONCLUSIONS: This case emphasizes the importance of the differential diagnosis when dealing with patients on immune checkpoint inhibitors because other non-immune-related events may present. Our patient was finally diagnosed with immune-related hyperthyroidism and a concurrent pituitary macroadenoma. This case also highlights the importance of a prompt start of corticosteroid therapy once immune-related adverse events such as hypophysitis are suspected, because otherwise the outcome would be fatal. BioMed Central 2018-09-04 /pmc/articles/PMC6122676/ /pubmed/30176934 http://dx.doi.org/10.1186/s13256-018-1782-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Carril-Ajuria, Lucia
Jiménez-Aguilar, Elisabeth
Gómez-Martín, Carlos
Díaz-Pedroche, Carmen
An unsuspected complication with immune checkpoint blockade: a case report
title An unsuspected complication with immune checkpoint blockade: a case report
title_full An unsuspected complication with immune checkpoint blockade: a case report
title_fullStr An unsuspected complication with immune checkpoint blockade: a case report
title_full_unstemmed An unsuspected complication with immune checkpoint blockade: a case report
title_short An unsuspected complication with immune checkpoint blockade: a case report
title_sort unsuspected complication with immune checkpoint blockade: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122676/
https://www.ncbi.nlm.nih.gov/pubmed/30176934
http://dx.doi.org/10.1186/s13256-018-1782-0
work_keys_str_mv AT carrilajurialucia anunsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT jimenezaguilarelisabeth anunsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT gomezmartincarlos anunsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT diazpedrochecarmen anunsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT carrilajurialucia unsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT jimenezaguilarelisabeth unsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT gomezmartincarlos unsuspectedcomplicationwithimmunecheckpointblockadeacasereport
AT diazpedrochecarmen unsuspectedcomplicationwithimmunecheckpointblockadeacasereport